At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 33 enrolled
Drug / intervention
LY3493269 - SC +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of LY3493269 in Healthy Participants
In Brief
A Phase 1 clinical trial evaluating LY3493269 - SC, Placebo - SC, and 1 other intervention for Healthy. Completed, enrolled 33 participants across 1 site.
Detailed Summary
This study is being conducted to determine the side effects related to LY3493269 given as a single injection to healthy participants. Blood tests will be performed to check how much LY3493269 gets into the bloodstream and how long the body takes to get rid of it. Each enrolled participant will receive a single dose of LY3493269 or placebo. The study will last up to approximately 71 days for each participant, including screening.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesSingapore
Collaborators--
Timeline
Phase 1CompletedFinished
2020202120222023202420252026
First PostedNov 2019
Enrollment StartJan 2020
Primary CompletionMay 2020
TodayJul 2026
First PostedNov 26, 2019
Enrollment StartJan 10, 2020
Primary CompletionMay 11, 2020
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 6.6 years ago
Interventions
LY3493269 - SCdrug
Administered SC
Placebo - SCdrug
Administered SC
LY3493269 - IVdrug
Administered IV